Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures

Cancer Gene Therapy

Volumn 7, Issue 2, 2000, Pages 167-176

  Cignetti, Alessandro ^a,c   Guarini, Anna ^a   Gillio Tos, Anna ^a   Reato, Gigliola ^a   Foa, Robert ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Gene therapy; Immunotherapy; Interleukin 2; Interleukin 7; Leukemia

Indexed keywords

CD56 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 7;

ARTICLE; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; LEUKEMIA; LEUKEMIA CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MIXED LYMPHOCYTE CULTURE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0034113964     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700107     Document Type: Article

References (45)

1. Foa R, Fierro MT, Tosti S, et al. Induction and persistence of complete remission in a resistant acute myeloid leukemia patient after treatment with recombinant interleukin-2. Leuk Lymphoma. 1990;1:113-117.
2. Foa R, Meloni G, Tosti S, et al. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. Br J Haematol. 1991;77:491-496.
3. Maraninchi D, Blaise D, Viens P, et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood. 1991;78:2182-2187.
4. Lim SH, Newland AC, Kelsey S, et al. Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia: a phase II study. Cancer Immunol Immunother. 1992;34:337-342.
5. Meloni G, Foa R, Vignetti M, et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood. 1994;84:2158-2163.
6. Gottlieb DJ, Prentice HG, Heslop HE, et al. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood. 1989;74:2335-2342.
7. Foa R, Guarini A, Gillio Tos A, et al. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine-activated killer cell generation. Cancer Res. 1991;51:964-968.
8. Chen W, Peace DJ, Rovira DK, et al. T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci USA. 1992;89:1468-1472.
9. Lim SH, Coleman S. Chronic myeloid leukemia as an immunological target. Am J Hematol. 1997;54:61-67.
10. Gambacorti-Passerini C, Grignani F, Arienti F, et al. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/ RARα present in acute promyelocytic leukemia cells. Blood. 1993;81:1369-1375.
11. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989;57: 503-512.
12. Forni G, Parmiani G, Guarini A, et al. Gene transfer in tumor therapy. Ann Oncol. 1994;5:789-794.
13. Foa R, Guarini A, Gansbacher B. IL2 treatment for cancer: from biology to gene therapy. Br J Cancer. 1992; 66:992-998.
14. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990;60: 397-403.
15. + T cell-dependent tumor rejection. J Exp Med. 1991;174:1291-1298.
16. Connor J, Bannerji R, Saito S, et al. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med. 1993;177:1127-1134.
17. Arienti F, Sule Suso J, Melani C, et al. Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. Hum Gene Ther. 1994;5:1139-1150.
18. Guarini A, Gansbacher B, Cronin K, et al. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte. Cytokines Mol Ther. 1995;1:57-64.
19. Colombo MP, Forni G . Immunotherapy: cytokine gene transfer strategies. Cancer Metastasis Rev. 1997;16:421-432.
20. Miller AR, McBride WH, Dubinett SM, et al. Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunologic properties with interleukin-2. Blood. 1993;82:3686-3694.
21. Cignetti A, Guarini A, Carbone A, et al. Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. J Natl Cancer Inst. 1994;86:785-791.
22. Arione R, Jemma C, Forni M, et al. A new childhood T-cell lymphoma established in nude mice and in vitro. Cancer Res. 1988;48:1312-1318.
23. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1989;7:980-990.
24. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol. 1988;62:1120-1124.
25. Goodwin RG, Lupton S, Schmierer A, et al. Human interleukin-7: molecular cloning and growth factor activity on human and murine B-lineage cells. Proc Natl Acad Sci USA. 1989;86:302-306.
26. Sharma S. Interleukin-7 gene transfer in non-small-cell lung cancer decreases tumor proliferation, modifies cell surface molecule expression, and enhances antitumor reactivity. Cancer Gene Ther. 1996;3:302-313.
27. Mann R, Mulligan R, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983;33:153-159.
28. Zier K. Functional and antigenic properties of cultured T-cells in the cell-mediated lympholysis (CML) assay. Hum Immunol. 1982;4:147-156.
29. Rolink A, Kudo A, Karasuyama H, et al. Long-term proliferating early pre-B cell lines and clones with the potential to develop to surface Ig-positive, mitogen-reactive B cells in vitro and in vivo. EMBO J. 1991;10:327-336.
30. Rook AH, Kehrl JH, Wakefield LM, et al. Effects of transforming growth factor-β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol. 1986;136:3916-3920.
31. Kuppner MC, Hamou MF, Bodmer S, et al. The glioblastoma-derived T-cell suppressor factor/transforming growth factor β2 inhibits the generation of lymphokine-activated killer (LAK) cells. Int J Cancer. 1988;42:562-567.
32. Inge TH, Hoover SK, Susskind BM, et al. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor β1. Cancer Res. 1992;52:1386-1392.
33. Sporn MB, Roberts AB. The transforming growth factor-βs: past, present, and future. Ann N Y Acad Sci. 1990;593: 1-6.
34. Ruffini PA, Rivoltini L, Silvani A, et al. Factors, including transforming growth factor β, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother. 1993; 36:409-416.
35. Tada T, Ohzeki S, Utsumi K, et al. Transforming growth factor-β-induced inhibition of T cell function; susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol. 1991;146:1077-1082.
36. Dubinett SM, Huang M, Dhanani S, et al. Down-regulation of murine fibrosarcoma transforming growth factor-β1 expression by interleukin 7. J Natl Cancer Inst. 1995;87:593-597.
37. Fisch P, Weil Hillman G, Uppenkamp M, et al. Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with acute T-cell leukemia. Blood. 74:1989:343-353.
38. Clinical protocols worldwide. Cancer Gene Ther. 1996;4: 265-278.
39. Hirst WJR, Buggins A, Darling D, et al. Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1. Gene Ther. 1997;4:691-699.
40. Huang MR, Olsson M, Kallin A, et al. Efficient adenovirus-mediated gene transduction of normal and leukemic hematopoietic cells. Gene Ther. 1997;4:1093-1099.
41. Kato K, Cantwell MJ, Sharma S, et al. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998; 101:1133-1141.
42. Wendtner C-M, Nolte A, Mangold E, et al. Gene transfer of costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Ther. 1997;4:726-735.
43. Anderson R, Macdonald I, Corbett T, et al. Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus. Hum Gene Ther. 1997; 8:1125-1135.
44. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263-267.
45. Grignani F, Kinsella T, Mencarelli A, et al. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res. 1998;58: 14-19.